The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pathomics-based prediction of thymic epithelial tumor subtypes within the French RYTHMIC network.
 
Lodovica Zullo
Research Funding - Owkin (Inst)
 
Mathilde Bateson
Employment - Owkin
 
Jose Benitez-Montanez
No Relationships to Disclose
 
Audrey Mansuet-Lupo
No Relationships to Disclose
 
Damien Sizaret
No Relationships to Disclose
 
Juan Florez-Arango
No Relationships to Disclose
 
Alvaro Lopez-Gutierrez
No Relationships to Disclose
 
Daniela Miliziano
No Relationships to Disclose
 
Pascale Missy
No Relationships to Disclose
 
Vincent De Montpreville
No Relationships to Disclose
 
Olaf Mercier
No Relationships to Disclose
 
Jordi Remon Masip
Consulting or Advisory Role - AstraZeneca (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); OSE Immunotherapeutics
Travel, Accommodations, Expenses - AstraZeneca; Inivata; MSD Oncology; OSE Immunotherapeutics; OSE Immunotherapeutics; Roche/Genentech
 
David Planchard
Honoraria - Medscape; PeerVoice; Prime Oncology
Consulting or Advisory Role - Abbvie; Anheart Therapeutics; ArriVent Biopharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/Astra Zeneca; Ellipses Pharma; Gilead Sciences; Janssen; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Samsung; Seagen
Research Funding - Abbvie (Inst); ArriVent Biopharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi/Aventis (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Nicolas Girard
Employment - AstraZeneca (I)
Consulting or Advisory Role - Abbvie; AMGEN; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Ipsen; Janssen; LEO Pharma; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); MSDavenir (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; Janssen Oncology; Roche
 
Thierry Molina
Consulting or Advisory Role - Merck; Novartis
Travel, Accommodations, Expenses - Takeda
 
Benjamin Besse
Honoraria - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); OSE Immunotherapeutics (Inst); Sanofi/Aventis (Inst); SERVIER (Inst)
Consulting or Advisory Role - Abbvie (Inst); beijin avistone (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); CureVac (Inst); Ellipses Pharma (Inst); F. Hoffmann LaRoche (Inst); Foghorn Therapeutics (Inst); Immunocore (Inst); Lilly (Inst); Owkin (Inst); PharmaMar (Inst); Regeneron (Inst); Sanofi/Aventis (Inst)
Research Funding - Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); CureVac (Inst); Daiichi Sankyo Europe GmbH (Inst); Enliven Therapeutics (Inst); Genmab (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); OSE Immunotherapeutics (Inst); PharmaMar (Inst); Prelude Therapeutics (Inst); Sanofi (Inst); Takeda (Inst)